Longitudinal development of obesity in the post-Fontan population

K Wellnitz1, I S Harris2,3, A Sapru1

  • 1Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of California, San Francisco, CA, USA.

Insights

Childhood obesity is a risk for heart conditions. After Fontan surgery for congenital heart disease, overweight and obesity increase over five years, particularly in Hispanic children.

Area of Science:

  • Pediatric Cardiology
  • Cardiovascular Health
  • Obesity Research

Background:

  • Elevated Body Mass Index (BMI) in childhood is a known cardiovascular disease risk factor.
  • This risk may be amplified in individuals with palliated univentricular congenital heart disease.
  • Longitudinal data on obesity development in this specific population is limited.

Purpose of the Study:

  • To determine the prevalence of overweight (OW) and obesity (OB) at Fontan palliation.
  • To track BMI changes in the post-Fontan period.
  • To investigate associations between demographic/clinical factors and later OW/OB development.

Main Methods:

  • Retrospective chart review of 84 patients undergoing Fontan palliation.
  • Collection of demographic data: gender, ethnicity, heart defect, ventricular dominance.
  • Yearly measurement of height, weight, and BMI for five years post-surgery.

Main Results:

  • 10.7% of patients were overweight or obese at Fontan palliation.
  • The prevalence of overweight/obesity increased from 20.3% at 1 year to 30% at 5 years post-Fontan.
  • Hispanic ethnicity was significantly associated with increased BMI Z-scores post-Fontan (P<0.001).

Conclusions:

  • A trend of increasing overweight and obesity exists in the first five years after Fontan palliation.
  • Hispanic ethnicity is significantly associated with overweight/obesity both pre- and post-surgery.
  • Further research is required to link overweight/obesity status to health outcomes in this cohort.
Abstract

Related Concept Videos

Longitudinal Research02:20

Longitudinal Research

Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...
13.7K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Longitudinal Studies01:26

Longitudinal Studies

Longitudinal studies are also widely used in other medical and social science fields. For instance, in cardiovascular research, they can monitor patients' health over decades to identify risk factors for heart disease, such as high cholesterol or smoking, and evaluate the long-term effectiveness of preventive measures. Similarly, in mental health studies, researchers might follow individuals from adolescence into adulthood to understand the development and progression of conditions like...
692
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
404
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
349
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
306